• Proceedings of the Korean Society of Toxicology Conference
• /
• 2002.11b
• /
• pp.178-179
• /
• 2002

GX-12 is a naked DNA vaccine developed by Dong-A Pharmaceutical Company, Green Cross Company and Genexine for the treatment of HIV infection. GX-12 consists of four separate plasmids. This study was performed to investigate the autoimmunogenic potential of GX-12 using primary and secondary PLNA method, and to examine the induction of autoantibodies in mice immunized with GX-12.(omitted)

• Proceedings of the Korean Society of Toxicology Conference
• /
• 2002.11b
• /
• pp.199-200
• /
• 2002

GX-12 is a naked DNA vaccine developed by research team of Dong-A Pharmaceutical Company, Green Cross Company and Genexine for the treatment of HIV infection. It consists of four separate plasmids (pGX10-GE HX, pGX10-dpol JR, pGX10-VN/TV JR, pGX10-hIL-12m), which were constructed by inserting the HIV-1 gag-env, pol, regulatory genes and a human IL-12 mutant gene into pGX10 plasmid vectors.(omitted)

• Proceedings of the Korean Society of Toxicology Conference
• /
• 2002.11b
• /
• pp.201-201
• /
• 2002

GX-12 is a naked DNA vaccine developed by Dong-A pharmaceutical company for the treatment of mv infection. GX-12 consists of four separate plasmids. This study was performed to evaluate the biodistribution and expression of GX-12 mRNA in gonadal tissues, and to investigate the histopathological changes in rats after repeated intramuscular injection.(omitted)

• Toxicological Research
• /
• v.19 no.1
• /
• pp.13-19
• /
• 2003

GX-12 is a naked DNA vaccine developed by the DongA Pharmaceutical Co. Ltd. and Genexine for the treatment of HIV infection. This study was peformed to evaluate the biodistribution and expression of GX-12 mRNA in gonadal tissues, and to investigate the histopathological changes after the repeated intramuscular injection. GX-12 (400 $\mu\textrm{g}$/head) was injected into the left anterior tibialis once a week for four weeks. On day 1, 5, 15, 30 and 45 after the final administration, gonadal tissues (testes, epididymis, seminal vesicles, penis, prostate glands, ovaries, vagina, uterus) and the injection site (muscle) were harvested and examined for the expression of mRNA by RT-PCR. In addition, histopathological examination was peformed at each time point. At the injection site, mRNA expression of GX-12 was detected only at early time points (1 ~ 15 days after injection) but not thereafter. However, in gonadal tissues, mRNA expression was not identified at all time points both in male and female rats. There were no histopathological changes in all reproductive organs and muscle. Based on these results, it is unlikely that the plasmid DNAs of GX-12 was distributed to- and expressed in gonadal tissues, suggesting that the chance of germline integration and transmission is negligible.

• Archives of Pharmacal Research
• /
• v.26 no.6
• /
• pp.493-498
• /
• 2003

In this study we have investigated the pharmacokinetics and tissue distribution of GX-12, a multiple plasmid DNA vaccine for the treatment of HIV-1 infection. Plasmid DNA was rapidly degraded in blood with a half-life of 1.34 min and was no longer detectable at 90 min after intravenous injection in mice. After intramuscular injection, plasmid DNA concentration in the injection site rapidly declined to less than 1 ％ of the initial concentration by 90 min post-injection. However, sub-picogram levels (per mg tissue) were occasionally detected for several days after injection. The relative proportions of the individual plasm ids of GX-12 remained relatively constant at the injection site until 90 min post-injection. The concentration of plasmid DNA in tissues other than the injection site peaked at 90 min post-injection and decreased to undetectable levels at 8 h post-injection. The rapid in vivo degradation of GX-12 and absence of persistence in non-target tissues suggest that the risk of potential gene-related toxicities by GX-12 administration, such as expression in non-target tissues, insertional mutagenesis and germline transmission, is minimal.

• Proceedings of the Korean Society of Toxicology Conference
• /
• 2002.11b
• /
• pp.157-157
• /
• 2002

The toxicity of GX-12, a naked DNA vaccine developed by research team of Dong-A Pharmaceutical Company, Green Cross Company and Genexine for the treatment of HIV infection, was investigated in Sprague-Dawley rats. In single-dose intramuscular/oral acute toxicity studies, animals were treated 0, 250, 1000 or 4000 $\mu\textrm{g}$/kg/$m\ell$ in sodium phosphate buffer.(omitted)

• Proceedings of the Korea Environmental Mutagen Society Conference
• /
• 2002.11a
• /
• pp.178-179
• /
• 2002

• Proceedings of the Korea Environmental Mutagen Society Conference
• /
• 2002.11a
• /
• pp.157-157
• /
• 2002

• Proceedings of the Korea Environmental Mutagen Society Conference
• /
• 2002.11a
• /
• pp.199-200
• /
• 2002

• Proceedings of the Korea Environmental Mutagen Society Conference
• /
• 2002.11a
• /
• pp.201-201
• /
• 2002